The Stem Cell Transplant Daily
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Can they keep improving forever?
Key Points. Better clinical responses to teclistamab correlate with a more functional initial immune T-cell repertoire in the periphery and tumor siteMore
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Key Points. Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamabPati
Storytelling computers will change the course of human history, says the historian and philosopher
How a psychologist transformed economics
Blood Cancer Journal – Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis